TP53
Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax
American Journal of Hematology | February 19, 2026 | Volume: 101 | Issue: 4 | Pages: 866-871
10.1002/ajh.70248
| PMID 41708842